TO
Elite in Pulmonary Embolism
Check Dr. Thomas L. Ortel's experience treating your condition:
About Dr. Thomas L. Ortel

Thomas Ortel is a Hematologist in Durham, North Carolina. Ortel has been practicing medicine for over 37 years and is rated as an Elite expert by MediFind in the treatment of Pulmonary Embolism. He is also highly rated in 18 other conditions, according to our data. His top areas of expertise are Venous Thromboembolism (VTE), Antiphospholipid Syndrome, Deep Vein Thrombosis, Knee Replacement, and Hip Replacement. He is licensed to treat patients in North Carolina. Ortel is currently accepting new patients.

His clinical research consists of co-authoring 150 peer reviewed articles and participating in 20 clinical trials in the past 15 years. In particular, he has co-authored 18 articles and participated in 1 clinical trial in the study of Pulmonary Embolism.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Thomas L. Ortel it is best to call his office and ask if your insurance is accepted.

Accepts Medicare

Call to see if your plan is accepted.
Locations
40 Duke Medicine Cir, Durham, NC 27710
Background & Education
Graduate Institution
Indiana University School Of Medicine, 1985
Specialties
Hematology
Licenses
Internal Medicine in NC
Hospital Affiliations
Duke Regional Hospital
Duke University Hospital
Spartanburg Medical Center
Duke Raleigh Hospital
Languages Spoken
English
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


20 Clinical Trials

Genetics of Antiphospholipid Antibody Syndrome
Studies of Fondaparinux in Patients With Renal Dysfunction: PK Study of Fondaparinux in Outpatients With Renal Dysfunction
Bridging Anticoagulation in Patients Who Require Temporary Interruption of Warfarin Therapy for an Elective Invasive Procedure or Surgery
Pharmacokinetic Study of Fondaparinux in Inpatients With Renal Dysfunction
The Incidence of Thromboembolic Events in Patients With Antibodies to Heparin-PF4 After Cardiac Bypass
Adjuvant Low Dose Rituximab for Acquired TTP With Severe ADAMTS13 Deficiency
Determination of the Optimal Prophylactic Platelet Dose Strategy to Prevent Bleeding in Thrombocytopenic Patients (A TMH CTN Study)
Red Cell Storage Duration Study
STAR - Study of TTP and Rituximab, A Randomized Clinical Trial
HIT Observational Thromboembolism Study (A TMH CTN Study)
Study of Hemostasis and Invasive Procedures (SHIP: A TMH CTN Study)
Initial Treatment of Patients With Immune Thrombocytopenic Purpura: The ITP^2 Study
Apixaban for the Secondary Prevention of Thromboembolism: a Prospective Randomized Outcome Pilot Study Among Patients With the AntiphosPholipid Syndrome
Comparison of Oral Anticoagulants for Extended VEnous Thromboembolism (COVET)
View 17 Less Clinical Trials -

Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors
Advanced
Advanced
Advanced